Safety Study of NNZ-2566 in Healthy Female Subjects

Phase 1 Completed 39 enrolled Neuren Pharmaceuticals Limited

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to obtain evidence of the safety of NNZ-2566 in healthy female volunteers and to determine the pharmacokinetics (PK) of NNZ-2566 in healthy female volunteers.

Timeline

Start: 2010-03
Primary completion: 2010-08
Completion: 2010-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Trofinetide	Peptide	—	Intravenous

Safety Study of NNZ-2566 in Healthy Female Subjects

Summary

Timeline

Drugs

Indications